benign EDs are applicable and the predicted risk of malignancy using ADNEX without CA125 is <1%, the mass may be considered at low risk of malignancy. When the risk of malignancy is between 1% and 19%, the mass may be considered at intermediate risk. In case of risk ≥20%, the mass may be considered at high risk and the patient should be referred to oncology care. Objectives: Recent validation studies and systematic reviews with meta-analysis concluded that International Ovarian Tumor Analysis (IOTA) algorithms, such as the Simple Rules (SRs), are the best available tests to discriminate between benign and malignant adnexal masses prior to surgery. More recently, the IOTA group developed the Simple Rules Risk (SRR) model and the Assessment of Different NEoplasias in the adneXa (ADNEX) model. Our objective was to perform a prospective validation study of the above methods. Methods: International multicentre cohort study involving 3376 patients recruited between 2012 and 2015 (IOTA phase 5 interim analysis). Patients were recruited from 17 centres in 6 countries. All subjects had at least one adnexal tumour and underwent a standardised transvaginal ultrasound prior to selection for surgery. Gold standard was the histopathological diagnosis of the adnexal mass. Diagnostic performance of ADNEX (without the use of serum CA125) and SRR to discriminate between benign and malignant masses was assessed using the area under the receiver-operator characteristic curve (AUC). Meta-analytic techniques (random-effects models) were used to account for the heterogeneity between centres. For SRs sensitivity and specificity were calculated. Results: Malignancy rate was 35%. AUCs (95% confidence interval) for ADNEX without CA125 and SRR were 0.923 (0.906-0.936) and 0.905 (0.886-0.922), respectively. The SRs were inconclusive in 797 (24%) patients. Excluding inconclusive cases, sensitivity and specificity (95% confidence interval) for SRs were 87.7% (81.9-91.8%) and 95.7% (93.1-97.4%), respectively. When classifying inconclusive patients as malignant, sensitivity and specificity (95% confidence interval) for SRs were 92.5% (89.1-95.0%) and 77.4% (73.1-81.2%), respectively. Conclusions: This study shows that the established SRs and more recently developed prediction models ADNEX and SRR have very good performance on prospective validation.
Objectives: Recent validation studies and systematic reviews with meta-analysis concluded that International Ovarian Tumor Analysis (IOTA) algorithms, such as the Simple Rules (SRs), are the best available tests to discriminate between benign and malignant adnexal masses prior to surgery. More recently, the IOTA group developed the Simple Rules Risk (SRR) model and the Assessment of Different NEoplasias in the adneXa (ADNEX) model. Our objective was to perform a prospective validation study of the above methods. Methods: International multicentre cohort study involving 3376 patients recruited between 2012 and 2015 (IOTA phase 5 interim analysis). Patients were recruited from 17 centres in 6 countries. All subjects had at least one adnexal tumour and underwent a standardised transvaginal ultrasound prior to selection for surgery. Gold standard was the histopathological diagnosis of the adnexal mass. Diagnostic performance of ADNEX (without the use of serum CA125) and SRR to discriminate between benign and malignant masses was assessed using the area under the receiver-operator characteristic curve (AUC). Meta-analytic techniques (random-effects models) were used to account for the heterogeneity between centres. For SRs sensitivity and specificity were calculated. Objectives: With increasing use of ultrasound examination in pregnancy the detection of incidental adnexal masses has become a more common scenario. Ultrasound is proposed as being the first-choice modality to evaluate these masses in pregnancy. The majority of cases are managed expectantly, unless suspicious features of malignancy or any complications such as torsion occur. Malignant adnexal masses in pregnancy are known to be rare. Methods: In a retrospective cohort study in a tertiary referral centre in central London between 12/01/2014 and 14/11/2016 we have analysed the characteristics, nature, size and subsequent management of 41 cases of adnexal masses in early pregnancy. Included are pregnant women who underwent a transvaginal ultrasound scan <15 weeks of gestation and were found to have adnexal masses. In total 6 women have been excluded one with a corpus luteum cyst and five with reproductive-assisted pregnancies. Results: 41 women have been included in the study. The mean diameter of ovarian cysts was 47.7mm (95%CI:39.9-55.4). Mean gestation at time of first ultrasound was 7.4 weeks (95%CI:6.6-8.3). In 37 women ultrasound only was performed to reach diagnosis, one had an MRI scan, one had tumour markers and in two patients an MRI scan and tumour markers were performed. The most common diagnosis was mature teratoma in 20/41 women. One borderline tumour was found. 33/41 (80.5%) did not require any surgical intervention. 8/41 women underwent surgical intervention; six had major surgery under GA and two had cyst aspiration under local anesthesia in pregnancy. There was a significant difference in the mean diameter of ovarian cysts in the expectant management group (41.2mm; 95%CI:34.7-47.7) and the mean diameter of cysts in the surgically managed group (74.5mm; 95%CI: 49.2-99.8). Conclusions: Invasive cancer in pregnancy is rare. The results show a significant relation between the size of adnexal mass and the probability of surgery. Ultrasound examination of adnexal masses has been proven to be accurate and safe in pregnancy. Managing ovarian cysts in pregnancy can be challenging.
